Posted by Michael Wonder on 01 Jun 2020
New combination therapy now reimbursed for Australians living with incurable blood cancer
1 June 2020 - New combination therapy now reimbursed for Australians living with incurable blood cancer.
Australians living with the incurable blood cancer, multiple myeloma now have access to a new treatment option with today’s listing of Revlimid (lenalidomide) in combination with bortezomib and dexamethasone on the Pharmaceutical Benefits Scheme (PBS).
The three drug regimen will be reimbursed on the PBS for the treatment of all newly diagnosed multiple myeloma patients, irrespective of transplant eligibility, from 1 June 2020.
